Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care.

The Sentinel System is a national electronic postmarketing resource established by the US Food and Drug Administration to support assessment of the safety and effectiveness of marketed medical products. It has built a large, multi-institutional, distributed data network that contains comprehensive electronic health data, covering about 700 million person-years of longitudinal observation time nationwide. With its sophisticated infrastructure and a large selection of flexible analytic tools, the Sentinel System permits rapid and secure analyses, while preserving patient privacy and health-system autonomy. The Sentinel System also offers enhanced capabilities, including accessing full-text medical records, supporting randomized clinical trials embedded in healthcare delivery systems, and facilitating effective collection of patient-reported data using mobile devices, among many other research programs. The nephrology research community can use the infrastructure, tools, and data that this national resource offers for evidence generation. This review summarizes the Sentinel System and its ability to rapidly generate high-quality, real-world evidence; discusses the program's experience in, and potential for, addressing gaps in kidney care; and outlines avenues for conducting research, leveraging this national resource in collaboration with Sentinel investigators.

[1]  Mia Gallagher,et al.  Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks , 2018, American journal of epidemiology.

[2]  Jason Roy,et al.  Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. , 2017, Journal of comparative effectiveness research.

[3]  Vlado Perkovic,et al.  Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  W Katherine Yih,et al.  Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. , 2012, American journal of epidemiology.

[5]  S Toh,et al.  Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association , 2016, Clinical pharmacology and therapeutics.

[6]  Richard Platt,et al.  The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.

[7]  Alexandra-Chloé Villani,et al.  The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[8]  Thomas P. Gross,et al.  The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.

[9]  Lesley H. Curtis,et al.  Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data , 2019, Supportive Care in Cancer.

[10]  Mark L Unruh,et al.  Primary care physicians’ familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study , 2014, BMC Nephrology.

[11]  J. Zhang,et al.  Use of Mepolizumab Among Individuals with Asthma in the U.S. , 2020 .

[12]  Andrew Davenport,et al.  Phenotype Standardization for Drug Induced Kidney Disease , 2015, Kidney international.

[13]  Richard Platt,et al.  Four health data networks illustrate the potential for a shared national multipurpose big-data network. , 2014, Health affairs.

[14]  J. C. Maro,et al.  SAT0140 Risk of venous thromboembolism in rheumatoid arthritis patients treated with biologic and non-biologic dmards , 2018, Saturday, 16 JUNE 2018.

[15]  G. Niklas Norén,et al.  Temporal pattern discovery in longitudinal electronic patient records , 2010, Data Mining and Knowledge Discovery.

[16]  Andrew Bate,et al.  Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools , 2018, Pharmacoepidemiology and drug safety.

[17]  W Katherine Yih,et al.  Intussusception risk after rotavirus vaccination in U.S. infants. , 2014, The New England journal of medicine.

[18]  Vinit Nair,et al.  FDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial , 2018, Clinical trials.

[19]  Sebastian Schneeweiss,et al.  Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic , 2018, Epidemiology.

[20]  Robert L Davis,et al.  Drug safety data mining with a tree‐based scan statistic , 2013, Pharmacoepidemiology and drug safety.

[21]  R. Platt,et al.  Distributed Health Data Networks: A Practical and Preferred Approach to Multi-Institutional Evaluations of Comparative Effectiveness, Safety, and Quality of Care , 2010, Medical care.

[22]  R. Platt,et al.  Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.

[23]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[24]  Vinit Nair,et al.  Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). , 2020, American heart journal.

[25]  M. Perazella,et al.  Pharmacology behind Common Drug Nephrotoxicities. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[26]  W. Cheungpasitporn,et al.  Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis , 2015, PloS one.

[27]  Bruce H Fireman,et al.  Comparison of privacy‐protecting analytic and data‐sharing methods: A simulation study , 2018, Pharmacoepidemiology and drug safety.

[28]  W Katherine Yih,et al.  Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results , 2019, PLoS medicine.

[29]  Christian Hampp,et al.  Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis , 2019, Diabetes Care.

[30]  Michael Nguyen,et al.  The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise , 2012, Pharmacoepidemiology and drug safety.

[31]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[32]  Richard Platt,et al.  Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks , 2020, Clinical pharmacology and therapeutics.

[33]  Shayan Shirazian,et al.  Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. , 2020, Journal of the American Society of Nephrology : JASN.

[34]  Kenneth G Saag,et al.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.

[35]  Richard Platt,et al.  Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018 , 2019, PloS one.

[36]  Richard Platt,et al.  Design of a National Distributed Health Data Network , 2009, Annals of Internal Medicine.

[37]  Sascha Dublin,et al.  Studying Medication Safety in Pregnancy: A Call for New Approaches, Resources, and Collaborations , 2020, Pediatrics.

[38]  Adrian F Hernandez,et al.  Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.

[39]  Sengwee Toh,et al.  Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants , 2018, Pharmacoepidemiology and drug safety.

[40]  Kristian B Filion,et al.  Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases , 2014, BMJ : British Medical Journal.

[41]  Kamlesh Khunti,et al.  Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. , 2020, The lancet. Diabetes & endocrinology.

[42]  Yea-Huei Kao Yang,et al.  Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies , 2017, European Journal of Epidemiology.

[43]  Kamlesh Khunti,et al.  SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. , 2018, Primary care diabetes.